ProCE Banner Activity

LIBRETTO-001: Phase I Trial of LOXO-292, a Novel RET Inhibitor, in Patients With RET-Altered Advanced Solid Tumors

Slideset Download
Conference Coverage
LOXO-292 showed robust and durable activity in previously treated patients with RET-altered tumors, including NSCLC, regardless of prior therapy.

Released: June 05, 2018

Expiration: June 04, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen